Jade Biosciences, Inc. (JBIO) Earnings History
Net Loss6 years of earnings data (2020–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Jade Biosciences, Inc. (JBIO) Earnings Overview
As of July 8, 2026, Jade Biosciences, Inc. (JBIO) reported trailing twelve-month net income of -$130M, reflecting +95.2% year-over-year growth. The company earned $-2.24 per diluted share over the past four quarters.
Looking at the long-term picture, JBIO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$10M in fiscal 2020.
Jade Biosciences, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including KRYS ($225M net income, 52.6% margin), RCUS (-$369M net income, -142.9% margin), IMVT (-$506M net income), JBIO has comparable earnings metrics. Compare JBIO vs KRYS →
JBIO Earnings vs Peers
Earnings metrics vs comparable public companies
JBIO Historical Earnings Data (2020–2025)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$127M | -83.0% | -$114M | $-4.06 | - | - |
| 2024 | -$70M | +7.8% | -$75M | $-85.26 | - | - |
| 2023 | -$76M | -46.6% | -$81M | $-100.38 | - | - |
| 2022 | -$52M | -124.3% | -$53M | $-73.67 | - | - |
| 2021 | -$23M | -138.9% | -$23M | $-32.96 | - | - |
| 2020 | -$10M | - | -$9M | $-14.00 | - | - |
Download Data
Export JBIO earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
JBIO — Frequently Asked Questions
Quick answers to the most common questions about buying JBIO stock.
What is JBIO earnings per share (EPS)?
JBIO trailing twelve-month (TTM) diluted EPS is $-2.24, reflecting +95.2% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2020 to 2025 is available in the table on this page.
What is Jade Biosciences, Inc.'s net income?
Jade Biosciences, Inc. (JBIO) trailing twelve-month net income is $-130M as of 2025. Earnings grew +95.2% year-over-year.
Is JBIO profitable?
JBIO is not currently profitable on a TTM basis, reporting a net loss of $-130M. Net margin is N/A. Investors should monitor for a return to profitability.
What is JBIO's earnings growth rate?
JBIO compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2020 to 2025.
What are JBIO's profit margins?
Jade Biosciences, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -62.3%.
Is JBIO growing earnings?
Yes, JBIO earnings are accelerating — EPS growth of +95.2% exceeds the 5-year CAGR of N/A. TTM net income reached $-130M. Earnings momentum is strengthening.
What was JBIO's best earnings year?
Jade Biosciences, Inc.'s highest annual net income on record is $-10M, achieved in fiscal year 2020. Earnings history on this page spans 2020 to 2025 and includes all annual and quarterly figures.
What were JBIO's earnings last quarter?
JBIO's most recent reported quarter was Q1 2026. Net income was $-40M with diluted EPS of $-0.70. For a full breakdown of all quarters, see the quarterly earnings table on this page.